Kar Ven Cavan Chow

Kar Ven Cavan Chow

Auto-generated profile, based on publicly available information

Kar Ven Cavan Chow

Department of Medical Oncology, Royal Brisbane and Women’s Hospital, Herston, Australia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2022 in Oxford Medical Case Reports
Verified
Journal Article
Open access
PDF file
KCKar Ven Cavan Chow
Kar Ven Cavan Chow
COConnor O’Leary
Connor O’Leary
FPFiona Paxton-Hall
Fiona Paxton-Hall
DLDuncan Lambie
Duncan Lambie
KOKenneth O’bYrne
Kenneth O’bYrne
A 63-year-old man with metastatic lung adenocarcinoma presented with biopsy confirmed toxic epidermal necrolysis (TEN). Symptoms commenced following 3 cycles of carboplatin, pemetrexed and pembrolizumab, with the first cycle given ~9.5 weeks prior to presentation. The patient was managed with immunosuppressive therapy including high dose methylprednisolone, cyclosporine, intravenous immunoglobulin, antibiotics and optimal skin care, and achieved excellent recovery of the skin lesions with minimal sequelae. This rare occurrence of pembrolizumab-induced TEN has only been reported previously in a few cases with limited evidence on management. Given the increasing use of immune checkpoint inhibitors and the long half-life of these agents, our case highlights the importance of recognizing this complication and of a multidisciplinary approach to management.

23 October 2025 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
KCKar Ven Cavan Chow
Kar Ven Cavan Chow
KMKimberley Mui
Kimberley Mui
SHStewart Hunt
Stewart Hunt
CGChun Loo Gan
Chun Loo Gan
Background: Hemophagocytic lymphohistiocytosis is rare and does not have any distinct clinical features or laboratory abnormalities, whereby a high index of suspicion is required for diagnosis. Hemophagocytic lymphohistiocytosis can be divided into primary/genetic or secondary causes that can be immunotherapy-induced. With the increasing use of immune checkpoint inhibitors for treatment of multiple solid tumor malignancies, the incidence of rare complications such as hemophagocytic lymphohistiocytosis can be expected to rise. Case presentation: We describe a fatal case of immunosuppression-refractory pembrolizumab-induced hemophagocytic lymphohistiocytosis complicated by secondary disseminated fungal infection. A 75-year-old white Australian man with resected stage IIC melanoma who received four cycles of adjuvant pembrolizumab presented 11 weeks after commencement with febrile neutropenia, elevated C-reactive protein, and nonspecific symptoms. He developed progressive transaminitis, acute kidney injury, pancytopenia, hyperferritinemia, and hypofibrinogenemia. In addition, a bone marrow aspiration and trephine biopsy demonstrated hemophagocytosis. Treatment was commenced with high-dose corticosteroids and mycophenolate mofetil initially for suspected immune-related side effects, followed by tocilizumab and anakinra once a diagnosis of hemophagocytic lymphohistiocytosis was made. Unfortunately, his disease was refractory to treatment with development of multiorgan failure secondary to hemophagocytic lymphohistiocytosis, complicated by disseminated candidemia from prolonged immunosuppression, leading to death 26 days after admission. Conclusion: This case underscores the diagnostic complexities of hemophagocytic lymphohistiocytosis, the importance of a multidisciplinary approach to management, and the fatal side effects of extended immunosuppression. This also highlights the importance of the discussion of risks versus benefits of treatment, particularly in the adjuvant setting, emphasizing the rare but real risk of fatal toxicities. Prolonged immunosuppression can lead to severe complications, and judicious use of corticosteroids with intensive prophylaxis is crucial. Further research into the mechanism of checkpoint inhibitor-induced toxicities is critical in the era of immunotherapy to allow personalized immunosuppressive and steroid-sparing strategies in complex cases.

21 June 2024 in Asia-Pacific Journal of Clinical Oncology
Verified
Journal Article
Open access
KCKar Ven Cavan Chow
Kar Ven Cavan Chow
CTCassie Turner
Cassie Turner
BHBrett Hughes
Brett Hughes
ZLZarnie Lwin
Zarnie Lwin
BCBryan Chan
Bryan Chan
Aim: To evaluate the real‐world treatment patterns and outcomes for patients with pleural mesothelioma (PM) in the era of immunotherapy.Methods: This retrospective audit included patients with PM diagnosed within three tertiary referral centers in Queensland, Australia from January 2017 to July 2023. Patient and treatment characteristics and outcomes were recorded. Data was analyzed using descriptive statistics and the Kaplan‐Meier survival method.Results: A total of 90 patients were included: 84% were male, the median age was 75 years (range 70–79) and 85% had baseline Eastern Group Cooperative Group of 0–1. Subtypes included 54% epithelioid, 17% biphasic, 12% sarcomatoid, and 17% unspecified/unknown. First‐line treatment was received by 57/90 patients (63%) and 33/90 patients (37%) received the best supportive care (BSC). Chemotherapy was most used (63%) overall, but first‐line immunotherapy was more commonly used since ipilimumab/nivolumab was reimbursed by the Australian Pharmaceutical Benefits Scheme in July 2021. After first‐line treatment, only 40% received second‐line treatment and 60% received BSC.12‐month overall survival (OS) and progression‐free survival for all patients were 53% (95% confidence interval [CI]: 43–65) and 25% (95% CI 15–40) respectively. 12‐month OS was 72%, 64%, and 29% for immunotherapy, chemotherapy, and BSC, respectively. There was no significant difference in survival between chemotherapy and immunotherapy (hazard ratio 1.28, 95% CI: 0.65–2.5, p = 0.5).Conclusion: In our unselected real‐world cohort, both chemotherapy and immunotherapy are active against PM, but the prognosis remains guarded. There remains a need for better treatment options, especially in the first‐line setting. Enrolment in clinical trials is crucial to improving outcomes in this debilitating disease.

16 September 2021 in Urology Case Reports
Verified
Journal Article
Open access
KCKar Ven Cavan Chow
Kar Ven Cavan Chow
SHShahadat Hossain
Shahadat Hossain
We report a case of a 54-year-old man with a concurrent diagnosis of IgG4-related disease (IgG4-RD) and clear cell renal cell carcinoma (ccRCC) following asymptomatic submandibular lymphadenopathy with an incidental finding of a left renal mass. Partial nephrectomy revealed ccRCC with surrounding lymphoplasmacytic infiltrate, storiform fibrosis and a strong positivity for IgG4 on immunoperoxidase staining. The IgG4+:IgG + ratio was >40% and serum IgG4 levels were elevated at 159mg/dL. This case highlights the concurrent diagnosis of a unique dual pathology within the same organ and emphasises the importance of malignancy screening in patients with IgG4-RD and vice versa.